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failures and market withdrawal. Inspired by the "moneyball" approach used in baseball to 23 integrate diverse features to predict player success, we hypothesized that a similar 24 approach could leverage existing adverse event and tissue-specific toxicity data to learn 25 how to predict adverse events. We introduce MAESTER, a data-driven machine learning 26 approach that integrates information on a compound's structure, targets, and phenotypic 27 effects with tissue-wide genomic profiling and our toxic target database to predict the 28 probability of a compound presenting with different types of tissue-specific adverse 29 events. When tested on 6 different types of adverse events MAESTER maintains a high 30 accuracy, sensitivity, and specificity across both the training data and new test sets. 31
Additionally, MAESTER scores could flag a number of drugs that were approved, but later 32 withdrawn due to unknown adverse events -highlighting its potential to identify events 33 missed by traditional methods. MAESTER can also be used to identify toxic targets for 34 each tissue type. Overall MAESTER provides a broadly applicable framework to identify 35 toxic targets and predict specific adverse events and can accelerate the drug 36 development pipeline and drive the design of new safer compounds. 37 38 INTRODUCTION 39 40
Drug adverse events are currently one of the main causes of failure in drug development 41 and are one of the top 10 causes of death in the developed world 1, 2 . Toxicity issues 42 remain a leading cause for the rising clinical trial attrition rates 3, 4 . Even after a drug has 43 been approved, adverse drug reactions remain a large burden on the medical system 44 with the costs amounting to as much as $30 billion dollars annually in the USA 5 .
45
Furthermore the identification of the serious adverse events associated with drugs 46 frequently does not occur until after FDA approval, with as many as 50% of adverse 47 events going undetected during human trials 6 . Due to the prevalence and impact of this 48 problem, the U.S. Identifying determinants of tissue-specific toxicities and adverse events 87
We first sought to identify drugs or compounds that are specifically toxic within individual 88 tissues and compare them with compounds with no reported toxicities in these tissues.
89
We focused on a set of six tissues whose corresponding AEs are correlated with clinical 90 trial failures: liver, kidney, blood, heart, lung, and pancreas (Fig.S1A) We next examined how expression of a drug's targets could be used to predict TSAEs.
119
For this analysis we integrated tissue-specific expression data measured by the GTEX 120 database. For each toxic or safe drug in a given tissue set ( Fig.1A) , we quantified the 121 expression of all of that drug's targets in the specific tissue. Overall drugs with adverse 122 events in a specific tissue tended to also have higher target expression in that tissue than 123 their safe drug counterparts ( Fig.2A-E ). This information helps illustrate how it is 124 important to consider target based features and tissue-specific expression when 125 predicting adverse events. This analysis also confirms that high expression of a drug's 126 target in a given tissue can help predict toxicity in that tissue. 127 128
Distinct Patterns of Tissue-Specific Toxic and Safe Target Sets 129
Due to the significant relationship between drug target expression and related tissue 130 adverse events, we next sought to define a set of tissue-specific "toxic targets"-proteins 131 that are only targeted by drugs with known toxicity in that tissue -and "safe targets" -132 proteins only targeted by drugs with no related tissue toxicities. To do this, we begin by 133 taking the safe and toxic drug sets described in Fig.1A and identifying any targets 134 exclusive to each drug subset (Fig.2F ). Interestingly we found that though there was a 135 significant degree of overlap between the toxic and safe gene sets across multiple 136 tissues, there were a number of proteins identified that were specifically associated with 137 toxicity or non-toxicity in a single tissue ( Fig.2G-H ). For instance, ABL1 was flagged as a 138 toxic target in all six tissues, whereas KCNJ3 and KCNJ6 -proteins involved in voltage 139 gated potassium channels and the regulation of heartbeats -were only marked as toxic 140 targets in the heart. 141 142
To further investigate features of tissue-specific toxic targets we expanded the procedure 143 described in Fig.2F to generate toxic and safe targets for 30 different tissue types -144 including the 6 prior tested tissues. For each target, we computed a number of features, 145 including tissue-specific expression, network properties (betweenness and degree), loss 146 of function (LoF) mutation frequency, and essentiality status. We found that toxic gene 147 sets tend to be more connected in an aggregated protein-protein interaction network 148
( Fig.3A-B) , be more intolerant for LoF mutations (Fig.3C) , and be enriched for essential 149 genes (Fig.3D) . Finally, we used the ConsensusPathDB framework 16 to measure for GO 150 term enrichment and observed that for toxic gene sets the most commonly enriched terms 151
had to due with cell death, receptor signaling, and apoptotic processes (Fig.3E ) -152 pathways one would expect to be related to toxicity -whereas safe targets did not appear 153 to be related to any toxicity related processes (Fig.3F) Computational approach predicts likelihood of specific adverse events 159
To utilize these findings and more directly address the problem of adverse event 160 prediction, we developed MAESTER (a Moneyball Approach for Estimating Specific 161
Tissue adverse Events using Random forests) to compute the probability of a compound 162 presenting with a specific adverse event (Fig.4A) . To do this, we expanded upon the 163 framework of our previously published work on predicting broad clinical trial toxicities, 164
PrOCTOR 10 , and narrowed down the classification task to a set of specific adverse 165 events that are correlated with clinical toxicity and have high reported frequencies of 166 fatality in openFDA: drug-induced liver injury (DILI), nephrotoxicity, neutropenia, heart 167 attack, pleural effusion, and pancreatitis (Fig.S1A) . We began by using the framework 168 described in Fig.1A to define a training set of safe and toxic drugs for each adverse event 169
and its corresponding tissue. For the toxic drugs, we directly queried the database for 170 drugs that are linked to each adverse event or its synonyms. We then took drugs that are 171 not associated with any adverse event in the related tissue or any other severe adverse 172 events to be the set of safe drugs (Fig.S1B) . The set of keywords used to construct these 173 training sets are described in Table 1.  174  175 Building upon the framework of PrOCTOR, MAESTER integrates 13 structural features, 176 35 target and tissue features, and 8 drug similarity properties to produce a suite of 177 classifiers that are able to predict the likelihood of each adverse event (Fig.4A) We further assessed MAESTER's performance using an independent validation test set.
201
For liver toxicity, the FDA has curated the Liver Toxicity Knowledge Base (LTKB) that 202 classifies a number of compounds based on their risk of causing liver toxicity. We found 203 that MAESTER can significantly distinguish drugs that are of DILI-concern from those 204 classified as no concern using this independent database (Fig.4D) A feature importance analysis revealed that there is a subset of features that were 214 consistently predictive across all of MAESTER's adverse event models (Fig.S2A) . The 215 toxic and safe gene sets, structural and bioassay similarity features, polar surface area, 216 and expression of the drug target in mature B cells are important in a majority of models.
217
We also identified a subset of features that are uniquely predictive in specific models. For 218 example, target expression in digestive organs (e.g., colon, small intestine, stomach) 219
were highly important in the prediction of DILI (Fig.S2B) , expression in immune-related 220 cells (centroblasts, T cells, spleen) were important for neutropenia prediction (Fig.S2C) , 221 and the network degree of the drug target was the most important feature in prediction of 222 pleural effusion (Fig.S2D) .
224
We then compared the predictions for drugs across all models (Fig.S3A) . We found that 225 there were subsets of drugs that are predicted to be safe or toxic by most or all models.
226
We found that drugs predicted to have many TSAEs tended to have higher predicted 227 toxicity levels (measured by the PrOCTOR score) (Fig.S3B ) than drugs that were 228 predicted to have one or less TSAEs (Fig.S3C, p=1 .178e-06, Mann-Whitney U test). 229 230
MAESTER predicts specific adverse events for withdrawn drugs 231
To test MAESTER's ability to detect adverse events that may have been missed by 232 traditional approaches, we next focused on drugs that been approved but were later 233 withdrawn due to toxicity concerns. This is especially relevant because cardiotoxicity and 234 hepatotoxicity -two of MAESTER's adverse event models -are the largest causes of 235 toxicity related withdrawal 22 . We began by focusing on two well-known cases of drug 236 withdrawal -Vioxx and Avandia, both withdrawn for cardiac toxicity-and found that 237 MAESTER scored each as highly likely to cause cardiac toxicity ( Fig.5A-B) . In fact, 238
comparing Avandia (Rosiglitazone) to a less toxic analog (Pioglitazone) we observed that 239 the difference in reported toxicities corresponded to a difference in their MAESTER 240 scores. We found that these predictions did not change substantially when we removed 241 both drugs (and their analogs) from the original training set, retrained MAESTER's 242 underlying model, and rescored each compound. To further expand this analysis we 243 curated a list of withdrawn drugs (that were not part of MAESTER's original training set) 244
and their reason for withdrawal (Methods). For each drug we computed a MAESTER 245 probability corresponding to the specific reason for withdrawal ( Table 3) . We found that 246 for 87.5% of the withdrawn drugs MAESTER predicted that specific adverse event with a 247 probability greater than 0.5 -significantly more than would have been expected by 248 random chance (p =0.0003, Fisher's exact test). To further evaluate MAESTER's ability 249 to flag withdrawn drugs, we compared MAESTER probabilities of withdrawn drugs against 250 probabilities for drugs of similar indications that were never withdrawn and were not 251 known to have the reported adverse event (Fig.5C-F We have identified sets of toxic and safe drugs and genes that are associated with 273 adverse events in specific tissues. We found that tissue-specific toxic drugs tend to be 274 more similar to each other than known safe drugs and that their associated targets are 275 more highly expressed in corresponding tissues. We found tissue-specific toxic targets 276 tend to be enriched for apoptosis and cell death related biological processes, more 277 connected in protein-protein interaction networks, and are classified as more essential.
278
Leveraging this data, we developed MAESTER to combine compound and target 279
properties to predict the likelihood of specific adverse events. Because it is trained on 280 drugs with known adverse events, MAESTER can directly predict clinical effects 281 compared to cell or animal screening methods whose toxicity predictions may not 282 translate to the clinic. 283 284
One of the strengths of our big data approach is that it can consider a large number of 285 features without prior bias. This will become especially powerful in the coming years as 286 more large pharmacogenomics datasets become available to integrate. Analysis of these 287 features can aid in future drug design by providing insight into what types of drugs are 288 likely to be toxic and feeding this information back to the chemists. Additionally, while 289 toxicity is often modeled as a broad feature, often times it is a patient specific effect. As 290 more patient specific data becomes available MAESTER can be improved to predict 291 patient specific adverse events. This could be used to guide clinical trial design by 292 specifically selecting patients unlikely to present with toxic effects and radically change 293 how people approach precision medicine. 294
Figure 1 -A) Schematic describing the process by which we selected our toxic and 296 safe drugs for each specific tissue. B) Similarities of across all toxic drugs pairs, safe 297 drug pairs, and all combinations of toxic and safe drugs for drug structures, C) gene 298 expression changes, D) growth efficacies, and E) bioassays. P values were calculated 299 using a Wilcoxon Rank Sum test. 300 Predictions for drugs with FDA warning labels for heart attacks, neutropenia, or pleural 317 effusion. 318 cardiac toxicity compared to approved drugs of the same class with no known cardiac 323
toxicities. E-F) MAESTER scores for drugs withdrawn for liver toxicity compared to 324 approved drugs of the same class with no known liver toxicities. All p values were 325 calculated using a Wilcoxon rank sum test. 
